AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Around 7% of the Indian population suffers from IBS
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
From only 80 Jan Aushadhi Kendras in 2014, there are around 11,000 units operating across the country today
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
Subscribe To Our Newsletter & Stay Updated